{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:52:33Z","timestamp":1785851553052,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01354-1","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:20:27Z","timestamp":1763716827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Proton Pump Inhibitors Attenuate the Effectiveness of Nivolumab Monotherapy in Patients with Advanced Gastric Cancer: A Retrospective Study"],"prefix":"10.1007","volume":"56","author":[{"given":"Mikumi","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-7908","authenticated-orcid":false,"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakazu","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1354_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.ejca.2014.01.029","volume":"50","author":"A Ferro","year":"2014","unstructured":"Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980\u20132011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50:1330\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.029.","journal-title":"Eur J Cancer"},{"key":"1354_CR2","unstructured":"Cancer Statistics in Japan. Cancer Information Services, Cancer type statistical information Gastric cancer. National Cancer Center, Japan. https:\/\/ganjoho.jp\/public\/cancer\/stomach\/patients.html [in Japanese]. Accessed Jun 2, 2025."},{"key":"1354_CR3","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer, version 2. (2022)."},{"key":"1354_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"key":"1354_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"key":"1354_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science"},{"key":"1354_CR7","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350:1084\u20139. https:\/\/doi.org\/10.1126\/science.aac4255.","journal-title":"Science"},{"key":"1354_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M V\u00e9tizou","year":"2015","unstructured":"V\u00e9tizou M, Pitt JM, Daill\u00e8re R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079\u201384. https:\/\/doi.org\/10.1126\/science.aad1329.","journal-title":"Science"},{"key":"1354_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29:1437\u201344. https:\/\/doi.org\/10.1093\/annonc\/mdy103.","journal-title":"Ann Oncol"},{"key":"1354_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","volume":"31","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and Poplar trials. Ann Oncol. 2020;31:525\u201331. https:\/\/doi.org\/10.1016\/j.annonc.2020.01.006.","journal-title":"Ann Oncol"},{"key":"1354_CR11","doi-asserted-by":"publisher","first-page":"716317","DOI":"10.3389\/fimmu.2021.716317","volume":"12","author":"Q Giordan","year":"2021","unstructured":"Giordan Q, Salleron J, Vallance C, Moriana C, Clement-Duchene C. Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors. Front Immunol. 2021;12:716317. https:\/\/doi.org\/10.3389\/fimmu.2021.716317.","journal-title":"Front Immunol"},{"key":"1354_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740\u20138. https:\/\/doi.org\/10.1136\/gutjnl-2015-310376.","journal-title":"Gut"},{"key":"1354_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","volume":"65","author":"MA Jackson","year":"2016","unstructured":"Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749\u201356. https:\/\/doi.org\/10.1136\/gutjnl-2015-310861.","journal-title":"Gut"},{"key":"1354_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/1750743X.2025.2491300","volume":"17","author":"M Shibano","year":"2025","unstructured":"Shibano M, Takahashi M, Nakatsukasa H, Ishigami Y, Toyokawa T, Taira K, Kawaguchi T, Nakamura Y, Kaneda H. Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer. Immunotherapy. 2025;17:331\u20138. https:\/\/doi.org\/10.1080\/1750743X.2025.2491300.","journal-title":"Immunotherapy"},{"key":"1354_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"key":"1354_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1354_CR17","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed Jun 16, 2025."},{"key":"1354_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/sim.4780050306","volume":"5","author":"EL Korn","year":"1986","unstructured":"Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5:255\u201360. https:\/\/doi.org\/10.1002\/sim.4780050306.","journal-title":"Stat Med"},{"key":"1354_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.11622\/smedj.2018152","volume":"60","author":"SH Koo","year":"2019","unstructured":"Koo SH, Deng J, Ang DSW, et al. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore. Singapore Med J. 2019;60:512\u201321. https:\/\/doi.org\/10.11622\/smedj.2018152.","journal-title":"Singapore Med J"},{"key":"1354_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1186\/1756-0500-7-605","volume":"7","author":"SA Sands","year":"2014","unstructured":"Sands SA, Tsau S, Yankee TM, Parker BL, Ericsson AC, LeVine SM. The effect of omeprazole on the development of experimental autoimmune encephalomyelitis in C57BL\/6J and SJL\/J mice. BMC Res Notes. 2014;7:605. https:\/\/doi.org\/10.1186\/1756-0500-7-605.","journal-title":"BMC Res Notes"},{"key":"1354_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97\u2013103. https:\/\/doi.org\/10.1126\/science.aan4236.","journal-title":"Science"},{"key":"1354_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2023.02.011","volume":"184","author":"A Wada","year":"2023","unstructured":"Wada A, Enokida T, Okano S, Sato M, Tanaka H, Ueda Y, Fujisawa T, Takeshita N, Tanaka N, Tahara M. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2023;184:30\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2023.02.011.","journal-title":"Eur J Cancer"},{"key":"1354_CR23","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1007\/s10147-025-02805-2","volume":"30","author":"M Takahashi","year":"2025","unstructured":"Takahashi M, Nakatsukasa H, Shibano M, Ishigami Y, Oka T, Tani Y, Kawaguchi T, Nakamura Y, Kaneda H. Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors. Int J Clin Oncol. 2025;30:1582\u201392. https:\/\/doi.org\/10.1007\/s10147-025-02805-2.","journal-title":"Int J Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01354-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:20:30Z","timestamp":1763716830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01354-1","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"8 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Keio University School of Medicine (approval number: 20241052). The study was conducted in accordance with the principles of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research involving Human Subjects by the Ministry of Education, Culture, Sports, Science, and Technology, and the Ministry of Health, Labour, and Welfare of Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The requirement for written informed consent was waived by the ethics review committee because of the retrospective design of the study. Accordingly, we provided patients with an opt-out option through the official website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}